ERBB3 and thyroid cancer: Similarly, BRAFV600E thyroid cancer cells can rapidly relieve the negative feedback-regulation of human epidermal growth factor receptor 3 (HER3/ErbB3) transcription and increase autocrine secretion of the HER2 and HER3 ligand neuregulin 1 in response to vemurafenib, which also does not occur as effectively in melanoma cells [68].